The Pediatric Sleep Study

Inclusion Criteria:

• Child is aged 4 to 16 years, inclusive, at screening.
• Parent or legal guardian reports current concerns about the child's sleep (for example, difficulty falling asleep, staying asleep, or keeping a consistent sleep routine) and confirms the child has no diagnosed sleep disorder.
• Parent or legal guardian can read and understand English.
• Parent or legal guardian can read, understand, and give informed consent on behalf of the child; the child gives age-appropriate assent where applicable.
• Parent or legal guardian can use a personal smartphone and download Chloe by People Science.
• Parent or legal guardian can receive shipment of the study product or placebo, and any wearable device, at an address within the United States.
• Parent or legal guardian can support the child in completing study assessments for up to 11 weeks.
• Child is willing and able to consume the gummy and can safely chew and swallow gummy products.
• Parent or legal guardian agrees to keep the child's current lifestyle, diet, bedtime routine, and physical activity for the whole study.
• Child has a regular sleep-wake cycle with a consistent bedtime and wake time (within about 1 hour on weekdays and weekends) for at least 3 weeks before baseline, and agrees to keep this schedule during the study.

Exclusion Criteria:

• No personal smartphone, no internet access, or unwilling to download Chloe.
• Child has a diagnosed sleep disorder needing medical management (for example, obstructive sleep apnea, narcolepsy, or restless leg syndrome).
• Child snores loudly on most nights, has been seen to stop breathing, gasp, or choke during sleep, or has been referred for a sleep evaluation that is not yet complete.
• Use of melatonin, prescription sleep medication, or other sleep aids (including over-the-counter antihistamines used for sleep and CBD or hemp products) within 28 days before screening, or expected use during the study.
• Regular caffeine intake of more than 1 caffeinated beverage (over 110 mg) per day, or unwillingness to keep caffeine intake stable and avoid caffeine after mid-afternoon.
• Use of a standalone magnesium supplement, or any dietary supplement marketed for sleep, stress, relaxation, mood, or focus, within 30 days before randomization or during the study. A stable-dose standard children's multivitamin is allowed.
• Any investigational therapy within 30 days before randomization.
• Known allergy or hypersensitivity to any study product or placebo ingredient, to Asteraceae (daisy family) plants, or to soy, egg, peanut, tree nuts, shellfish, milk, wheat, or sesame.
• Any medical, neurodevelopmental, or psychiatric condition that, in the Principal Investigator's opinion, may confound sleep outcomes or affect participation.
• Significant illness, disease, or condition that, in the Principal Investigator's opinion, may affect participation or outcomes.
• Unlikely to be able to comply with the study, or considered unsuited by the Principal Investigator.
• History or presence of a clinically diagnosed neurologic, cardiac, renal, hepatic, endocrine (including diabetes), pulmonary, biliary, or gastrointestinal condition. Well-controlled asthma managed with as-needed medication, seasonal allergies, and mild eczema are not exclusions.
• Body mass index at or above the 95th percentile for age and sex.
• Use of angiotensin-converting enzyme inhibitors, other magnesium-retaining drugs, or potassium-sparing diuretics.
• Other diseases or medications that might interfere with the study or put the participant's health at risk.
• Immune insufficiency (such as selective IgA deficiency, common variable immunodeficiency, or X-linked agammaglobulinemia).
• Taking any prescription medication or dietary supplement for anxiety, depression, mood, stress, focus, or attention-deficit/hyperactivity disorder.
• Known liver dysfunction.
• Use of systemic corticosteroids or immunosuppressant drugs.
• History of cancer within the past 5 years.
• Planned surgery or invasive medical procedures during the study.
• Planned travel during baseline or the use period that involves a time zone change or 2 or more consecutive nights away from the usual sleep environment.
• Parent or legal guardian cannot communicate with the study team or complete study procedures, or child has a condition that would prevent completing assent or assessments.
• Child or household member of an employee of People Science or the Sponsor (Unilever/Olly).
• Pregnant or breastfeeding (self-reported).
• Another child in the same household is already enrolled.